Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02344355 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
A Phase 2 study of Glioblastoma Multiforme, sponsored by Bryan Allen.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT02344355 is a Phase 2 study of Glioblastoma Multiforme that is active but no longer recruiting, run by Bryan Allen. The registered enrollment target is 90 participants, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02344355, a Phase 2 study of Glioblastoma Multiforme, is active but no longer recruiting, sponsored by Bryan Allen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION radiation therapy
- DRUG Ascorbic Acid
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02344355
The ClinicalTrials.gov registry entry for NCT02344355 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The listed sponsor is Bryan Allen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT02344355 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT02344355 about?
NCT02344355 is a clinical study titled "A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme". This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.
What is the current status of trial NCT02344355?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2017-03-13. Estimated completion is 2028-12.
What conditions does trial NCT02344355 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT02344355?
The interventions under investigation include: Temozolomide (DRUG), radiation therapy (RADIATION), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT02344355?
This trial is sponsored by Bryan Allen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02344355 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.